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Genus-b human papillomavirus (HPV) DNA has been detected in basal cell carcinoma (BCC) tumors, but most
epidemiologic studies have not observed associations between genus-b HPV seropositivity and BCC. A clinic-
based case–control study was conducted to investigate cutaneous HPV infection in BCC. BCC cases (n¼ 224)
were recruited from a dermatology clinic, and controls (n¼ 300) were patients who were screened negative for
skin cancer. Antibodies against cutaneous HPV types in genera a, b, g, mu, and nu were measured, and tumors
from a subset of BCC cases (n¼ 195) were tested for HPV DNA. Overall associations were observed between BCC
and seropositivity for HPV types in genus-a (odds ratio (OR)¼ 1.61; 95% confidence interval (CI)¼ 1.11–2.35),
g (OR¼ 1.78; 95% CI¼ 1.22–2.60), and mu (OR¼ 1.56; 95% CI¼ 1.06–2.30). BCC cases with b-HPV DNA in their
tumors were more likely to be b-HPV seropositive than controls (OR¼ 1.76; 95% CI¼ 1.03–3.01), with type-specific
associations observed for HPV8 and HPV23, whereas no association was observed between b-HPV seropositivity
and b-HPV DNA–negative BCC. No concordance between seropositivity and tumor DNA status was observed for
HPV types in genera a and g. In conclusion, the combined serology and tumor DNA results suggest that b HPV
types may have a role in BCC. Additional studies of BCC that assess HPV types in multiple genera are needed.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common cancer in the
United States (Chinem and Miot, 2011). UVR exposure is the
most important environmental risk factor for BCC. Despite
public awareness of the harmful effects of UVR exposure and
increased use of sunscreen products, the incidence of BCC
continues to rise each year.
DNA of cutaneous human papillomavirus (HPV) types has
been detected in non-melanoma skin cancer (NMSC), espe-
cially in immunosuppressed individuals. Although most stu-
dies have focused on HPV DNA detection in squamous cell
carcinoma (SCC) (Boxman et al., 2000; Pfister et al., 2003;
Struijk et al., 2003; Forslund et al., 2007; McBride et al., 2007;
Asgari et al., 2008; Cronin et al., 2008; Madan et al., 2010),
genus-b HPV DNA has also been detected in BCC tumors,
ranging from 8 to 55% (Shamanin et al., 1996; Harwood et al.,
2000; Wieland et al., 2000; Meyer et al., 2003; Forslund et al.,
2004; Andersson et al., 2008) in immunocompetent
populations. In addition, no single type has been observed
to predominate in skin cancers, and cutaneous HPV viral load
is low, at less than one copy per cell, requiring highly sensitive
techniques to detect viral DNA.
Evidence from the literature supports a potential role for
cutaneous HPV seropositivity in NMSC, particularly SCC
(Feltkamp et al., 2003; Struijk et al., 2006; Casabonne et al.,
2007; Karagas et al., 2010). Studies that have reported on the
association between seropositivity to any genus-b HPV type
overall and BCC have not observed statistically significant
associations (Feltkamp et al., 2003; Andersson et al., 2008;
Karagas et al., 2010). However, type-specific associations with
BCC have been observed for seropositivity to HPV8 and HPV20
among persons from the Netherlands (Feltkamp et al., 2003).
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The aim of the current study was to investigate the
association between cutaneous HPV infection and BCC,
incorporating multiple biomarkers of infection. To our knowl-
edge, this is a previously unreported case–control study in a
US population to investigate the association between BCC and
seroreactivity to cutaneous HPV types belonging to five
different genera, as well as present serological associations
between genus-a, b, or g HPV types and BCC stratified by the
presence of DNA of these HPV types in the tumor tissues.
RESULTS
As presented in Table 1, older age, male sex, p12 years of
education, light eye and hair color, occupational sunlight
exposure, cutaneous sensitivity and tanning ability to sunlight
exposure, and history of smoking were associated with BCC.
However, none of the risk factors presented in Table 1 were
associated with cutaneous HPV serostatus among the controls,
as previously described (Iannacone et al., 2012; data not
shown).
Genus-mu (odds ratio (OR)¼1.56; 95% confidence interval
(CI)¼1.06–2.30; P¼ 0.03) and genus-a (OR¼1.61; 95%
CI¼ 1.11–2.35; P¼0.01) HPV seropositivity was significantly
associated with BCC, with a greater risk observed among
individuals seropositive for X2 types in genus-a (OR¼1.75;
95% CI¼ 1.08–2.85; Ptrend¼0.01; Table 2). However, for
both genera, statistical significance was lost after correction for
multiple comparisons. A positive association between BCC
and genus-g HPV seropositivity was observed (OR¼1.78;
95% CI¼1.22–2.60; P¼ 0.003), and remained statistically
significant after correction for multiple comparisons. No
statistically significant associations were observed for genus-
b seropositivity or the polyomaviruses JC virus and KI virus
(Table 2). Analyses restricted to those aged 40–69 years
revealed only minor differences in the associations between
genus-specific HPV seropositivity and BCC compared with the
total study population (Table 2).
Sex-stratified analyses demonstrated a statistically signifi-
cant greater association between BCC and seropositivity to the
single type in genus-mu among women (OR¼2.46; 95%
CI¼ 1.40–4.30) compared with men (OR¼ 1.00; 95%
CI¼ 0.58–1.72; Pinteraction¼0.02; Table 3) within the total
study population, as well among individuals aged 40–69 years
(P¼ 0.007; data not shown). No significant differences were
observed by sex between BCC and seropositivity to HPV
type(s) in genera a, b, g, and nu (Table 3).
Among BCC cases, the greatest type-specific seroprevalence
was observed for HPV1, and it was statistically significantly
associated with BCC (OR¼1.56; 95% CI¼ 1.06–2.30;
Table 4). In genus-a, compared with controls, seropositivity
to HPV types 3 (OR¼ 1.70; 95% CI¼1.03–2.82) and 27
(OR¼2.18; 95% CI¼1.28–3.71) were significantly asso-
ciated with BCC; however, none of these associations
remained statistically significant after correcting for multiple
comparisons. No associations were observed between BCC
and genera b, g, or nu seropositivity (Table 4).
Of the 238 BCC tumor tissues (98.3%) that tested positive
for the b-globin gene, 120 (50.4%) tested positive for DNA to
at least one genus-b HPV type, including 43 tumors (18.1%)
with a single-type infection and 77 (32.4%) with multiple-type
infections (Table 5). Individuals with genus-b HPV DNA–
positive tumors were significantly older (mean age (SD)¼65.1
(12.2) compared with those with genus-b HPV DNA–negative
Table 1. Crude associations between demographic,
skin cancer, and lifestyle risk factors and BCC
Control
(n¼ 300) BCC (n¼ 224)
Variable n (%) n (%) OR (95% CI)
Age in years (mean, SD) 55.4 (11.7) 62.5 (11.9) 1.05 (1.04–1.76)
Age
18–39 28 (9.3) 8 (3.6) 1.00 (Reference)
40–49 54 (18) 28 (12.5) 1.82 (0.73–4.50)
50–59 104 (34.7) 46 (20.5) 1.55 (0.66–3.66)
60–69 85 (28.3) 67 (29.9) 2.76 (1.18–6.45)
70–80 29 (9.7) 75 (33.5) 9.05 (3.70–22.15)
Sex
Female 186 (62) 89 (39.7) 1.00 (Reference)
Male 114 (38) 135 (60.3) 2.48 (1.74–3.53)
Education
4 12 years 267 (90.2) 157 (77.3) 1.00 (Reference)
p 12 years 29 (9.8) 46 (22.7) 2.70 (1.63 -4.47)
Eye color
Dark brown 81 (27.3) 33 (16) 1.00 (Reference)
Blue 85 (28.6) 85 (41.3) 2.45 (1.48–4.06)
Green 48 (16.2) 21 (10.2) 1.07 (0.56–2.06)
Hazel 48 (16.2) 46 (22.3) 2.35 (1.33–4.17)
Light brown 35 (11.8) 21 (10.2) 1.47 (0.75–2.89)
Hair color
Black/brown 234 (78.3) 144 (69.9) 1.00 (Reference)
Blonde/red 65 (21.7) 62 (30.1) 1.55 (1.03–2.32)
Job in sun for X 3 months
No 216 (72.7) 114 (55.1) 1.00 (Reference)
Yes 81 (27.3) 93 (44.9) 2.18 (1.50–3.16)
History of blistering sunburn
No 95 (32) 54 (26.3) 1.00 (Reference)
Yes 202 (68) 151 (73.7) 1.32 (0.89–1.95)
Skin reaction to season’s first sun exposure
Tan or no change in skin color 44 (14.8) 22 (10.8) 1.00 (Reference)
Mild sunburn turns to a tan 136 (45.6) 61 (30.1) 2.03 (1.15–3.60)
Sunburn with or without blisters 118 (39.6) 120 (59.1) 0.9 (0.50–1.63)
Skin reaction to repeated sun exposure
It tans easily 174 (59) 99 (49.3) 1.00 (Reference)
It can tan if you work at it 99 (33.6) 87 (43.3) 1.55 (1.06–2.26)
It is unable to tan 22 (7.5) 15 (7.5) 1.20 (0.59–2.42)
Alcohol consumption
No drinks in past year 38 (12.8) 36 (17.6) 1.00 (Reference)
X 1 drink in the past year 260 (87.3) 169 (82.4) 0.69 (0.42–1.13)
Ever smoked 100 cigarettes
No 150 (50.2) 78 (38.2) 1.00 (Reference)
Yes 149 (49.8) 126 (61.8) 1.63 (1.13–2.34)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; OR,
odds ratio.
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tumors (mean age (SD)¼60.1 (11.7); Pwilcoxon¼ 0.001). No
additional factors listed in Table 1 were statistically signifi-
cantly associated with genus-b HPV DNA status in the tumor
(data not shown). In contrast to the high DNA prevalence
observed for genus-b HPV types, the prevalence for HPV
type(s) in genera a, g, and mu was much lower. Twenty (8.4%)
BCC tumors tested DNA positive to at least one genus-g HPV
type, seven (2.9%) tumors tested positive for genus-a HPV
DNA, although none were DNA positive for HPV2 or HPV3,
and only one (0.4%) BCC tumor tested HPV DNA positive for
the single type in genus-mu (Table 5). In addition, within
genus, only single-type infections were present in the tumors
for a and g HPV types, and a single tumor was DNA positive
for HPV27 in genus-a and HPV50 in genus-g.
Roughly half of the BCC cases (49.7%) were HPV DNA
positive, corresponding to at least one type in genus-b. When
comparing seropositivity between controls and BCC cases
stratified by HPV DNA status, a statistically significantly
greater seroprevalence of genus-b antibodies was observed
among BCC cases with HPV DNA–positive tumors compared
with controls (OR¼ 1.76; 95% CI¼1.03–3.01), whereas no
association was observed between genus-b seropositivity and
BCC cases negative for HPV DNA (OR¼ 1.06; 95%
CI¼ 0.65–1.72; Table 6). Of the 97 BCC cases with genus-b
HPV DNA–positive tumors, 36.1% tested seropositive for the
same HPV type detected in the tumor tissue (data not shown).
Among cases with HPV8 and HPV23 DNA–positive tumors,
statistically significant associations were observed between
BCC and seropositivity for HPV types 8 (OR¼2.77; 95%
CI¼ 1.11–6.94) and 23 (OR¼ 15.8; 95% CI¼1.60–155.0;
Table 6). No differences in seroprevalence were observed
between HPV DNA–negative BCC cases and controls for any
single HPV type in genus-b (Table 6).
Among the seven BCC cases with genus-a HPV DNA–
positive tumors, none was seropositive for the same genus-a
HPV type. In addition, compared with controls, the seropre-
valence for genus-a HPV types was greater among cases with
genus-a HPV DNA–positive (OR¼ 2.53; 95% CI¼0.55–
11.72) or DNA–negative tumor tissues (OR¼ 1.64; 95%
CI¼ 1.11–2.44; Table 6). Only 17 (8.7%) BCC cases had
genus-g HPV DNA–positive tumors (Table 6), of which one
tested seropositive for the same type (HPV50). Using the
controls as a common reference group, no association was
observed between genus-g seropositivity and BCC cases with
tumors that were HPV DNA positive (OR¼ 1.40; 95%
CI¼ 0.49–4.00), whereas a statistically significant positive
association was observed between genus-g HPV seropositivity
and BCC cases with tumors that were negative for g HPV DNA
(OR¼1.97; 95% CI¼1.31–2.97; Table 6).
DISCUSSION
To our knowledge, this is the first study to report seropreva-
lence for cutaneous HPV types from five different genera and
to include both serological and DNA-based markers of
infection for cutaneous HPV types in relation to BCC. Similar
associations with SCC have been previously reported
(Iannacone et al., 2012).
The current study did not observe an association between
overall genus-b seropositivity and BCC, which is consistent
with previous studies (Feltkamp et al., 2003; Andersson et al.,
2008; Karagas et al., 2010). However, stratified analyses
revealed that BCC cases with genus-b HPV DNA–positive
tumors were significantly more likely to have genus-b HPV
Table 2. Associations between genus-specific HPV
seroreactivity and BCC cases and controls
Control
(n¼ 300) BCC (n¼224) BCC (n¼141)
HPV genus n (%) n (%) OR (95% CI)1 OR (95% CI)2
Alpha
Seronegative 194 (64.7) 121 (54.0) 1.00 (Reference) 1.00 (Reference)
Seropositive 106 (35.3) 103 (46.0) 1.61 (1.11–2.35) 1.68 (1.09–2.59)
1 type 59 (19.7) 52 (23.2) 1.50 (0.94–2.38) 1.55 (0.91–2.65)
X2 types 47 (15.7) 51 (22.8) 1.75 (1.08–2.85) 1.84 (1.04–3.24)
ptrend¼ 0.01 ptrend¼0.02
Beta
Seronegative 119 (39.7) 72 (32.1) 1.00 (Reference) 1.00 (Reference)
Seropositive 181 (60.3) 152 (67.9) 1.32 (0.90–1.93) 1.07 (0.69–1.66)
1 type 47 (15.7) 42 (18.8) 1.35 (0.79–2.32) 0.93 (0.70–1.73)
2-3 types 51 (17.0) 40 (17.8) 1.30 (0.76–2.21) 1.30 (0.70–2.42)
4-8 types 36 (12.0) 36 (15.2) 1.75 (0.97–3.15) 1.01 (0.51–2.01)
48 types 47 (15.7) 36 (16.1) 1.02 (0.59–1.78) 1.08 (0.57–2.02)
ptrend¼ 0.43 ptrend¼0.72
Gamma
Seronegative 145 (48.3) 73 (32.6) 1.00 (Reference) 1.00 (Reference)
Seropositive 155 (51.7) 151 (67.4) 1.78 (1.22–2.60)3 1.58 (1.02–2.44)
1 type 63 (21.0) 71 (31.7) 2.06 (1.29–3.27)3 1.86 (1.09–3.17)
X2 types 92 (30.7) 80 (35.7) 1.59 (1.03–2.45) 1.38 (0.84–2.29)
ptrend¼ 0.03 ptrend¼0.17
Mu
Seronegative 204 (68.0) 138 (61.6) 1.00 (Reference) 1.00 (Reference)
Seropositive 96 (32.0) 86 (38.4) 1.56 (1.06–2.30) 1.38 (0.89–2.13)
Nu
Seronegative 266 (88.7) 198 (88.4) 1.00 (Reference) 1.00 (Reference)
Seropositive 34 (11.3) 26 (11.6) 1.00 (0.56–1.77) 1.25 (0.64–2.42)
Control antigens
JCV
Seronegative 108 (36.0) 62 (27.7) 1.00 (Reference) 1.00 (Reference)
Seropositive 192 (64.0) 162 (72.3) 1.32 (0.89–1.96) 1.34 (0.84–2.11)
KIV
Seronegative 24 (8.0) 14 (6.3) 1.00 (Reference) 1.00 (Reference)
Seropositive 276 (92.0) 210 (93.8) 0.88 (0.42–1.83) 0.81 (0.35–1.88)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HPV,
human papillomavirus; JCV, JC virus; KIV, KI virus; OR, odds ratio.
1OR and 95% CI adjusted for age and sex.
2OR and 95% CI adjusted for age and sex, restricted to participants aged
40–69 years. The age-restricted analysis included 141 BCC cases and 243
controls.
3Statistical significance retained after correction for multiple comparisons
(b-coefficient Po0.01).
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antibodies compared with controls. In addition, among BCC
cases DNA positive for HPV types 8 and 23, a higher
seroprevalence for the same type was observed in the cases
compared with the controls. These results may indicate that
HPV infection is involved in some but not all skin cancers, and
as a result the association between genus-b HPV seropositivity
and BCC would be obscured when HPV DNA status of the
tumors is not taken into account.
In the current study, BCC was associated with genus-a
seropositivity, with type-specific associations observed for
HPV3 and HPV27. The single published study reporting results
for BCC and seroreactivity to cutaneous HPV types outside of
genus-b (Andersson et al., 2008) reported a null association
with genus-a seropositivity. Differences across study findings
may be due to differences in the HPV types and number of
types investigated. Only seven BCC tumors were DNA
positive for genus-a HPV types; however, no tumors were
positive for HPV3 and only two were positive for HPV27.
Regardless of HPV DNA status in the tumors, seroprevalence
was greater among BCC cases compared with controls. These
findings may indicate that seroresponse for genus-a HPV types
is not related to the presence of DNA for these types in the
tumor. In addition, if in fact genus-a HPV types are involved in
BCC development, the low detection of these HPV types in the
tumor tissues may indicate that HPV has a role in the earlier
stages of skin cancer tumorigenesis. A similar phenomenon
may hold true for the single HPV type in genus-mu, where
38% of BCC cases were observed to be seropositive while
DNA for HPV1 was detected in a single tumor tissue only.
A statistically significant association was observed between
genus-g HPV seropositivity and BCC; however, only 8.4% of
BCC tumors were DNA positive for genus-g HPV types.
Furthermore, when stratified by the presence or absence of
DNA in the tumor tissue, an association with genus-b HPV
Table 3. Associations between (a) genus-specific HPV seroreactivity and BCC stratified by sex; (b) genus-specific
seropositivity and BCC stratified by gender, restricted to population aged 40–69 years
Male (n¼249) Female (n¼275)
HPV genus n (%) OR (95% CI)1 n (%) OR (95% CI)1 P-value2
(a)
Alpha
Seronegative 145 (58.2) 1.00 (Reference) 170 (61.8) 1.00 (Reference)
Seropositive 104 (41.8) 1.92 (1.13-3.27) 105 (38.2) 1.35 (0.79-2.29) 0.36
Beta
Seronegative 83 (33.3) 1.00 (Reference) 108 (39.3) 1.00 (Reference)
Seropositive 166 (66.7) 1.24 (0.72-2.13) 167 (60.7) 1.39 (0.81-2.39) 0.76
Gamma
Seronegative 87 (34.9) 1.00 (Reference) 131 (47.6) 1.00 (Reference)
Seropositive 162 (65.1) 1.64 (0.95-2.81) 144 (52.4) 1.93 (1.13-3.28) 0.67
Mu
Seronegative 162 (65.1) 1.00 (Reference) 180 (65.5) 1.00 (Reference)
Seropositive 87 (34.9) 1.00 (0.58-1.72) 95 (34.5) 2.46 (1.40-4.30) 0.02
Nu
Seronegative 216 (86.8) 1.00 (Reference) 248 (90.2) 1.00 (Reference)
Seropositive 33 (13.2) 1.00 (0.47-2.12) 27 (9.8) 0.99 (0.40-2.42) 0.99
(b)
Male (age 40–69, n¼177) Female (age 40–69, n¼207)
HPV Genus OR (95% CI)1 OR (95% CI)1
Alpha 2.05 (1.11-3.79) 1.37 (0.73-2.55)
Beta 1.13 (0.61-2.09) 1.01 (0.55-1.88)
Gamma 1.43 (0.77-2.66) 1.74 (0.94-3.22)
Mu 0.83 (0.45-1.52) 2.37 (1.27-4.43)
Nu 1.30 (0.54-3.12) 1.19 (0.43-3.31)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HPV, human papillomavirus; OR, odds ratio.
1Adjusted for age.
2P-value for b-coefficient corresponding to the genus-specific HPV sex interaction term in logistic regression model.
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seropositivity was observed among BCC cases with HPV
DNA–negative tumors but not among BCC cases with DNA-
positive tumors. This trend is contrary to that observed for
genus-b HPV seropositivity in relation to DNA status in the
tumor. No other studies have presented information on genus-
g HPV seroreactivity or detection of DNA in tumor tissue
among BCC cases. Furthermore, there is no information
available on the functionality of genus-g HPV types. Thus,
other than chance, the explanation for the observed associa-
tion between genus-g seropositivity and g-HPV DNA–negative
BCC is unknown.
The associations with BCC observed in the present analysis
differ from those previously reported for SCC from the same
underlying clinic population (Iannacone et al., 2012), with
seroprevalence being significantly elevated for genus-b HPV
types in SCC but for genus-g types in BCC. In addition, in
genus-a, HPV10 seropositivity was associated with SCC,
whereas HPV types 3 and 27 were associated with BCC.
The observed differences in risk of cutaneous HPV infection
by NMSC type within the same study population support the
hypothesis that these malignancies have distinct etiologies.
Recent evidence in vitro demonstrated functional differences
in the E6 and E7 oncoproteins encoded for by different genus-
b HPV types, as they relate to the life span and
immortalization of primary foreskin keratinocytes (Cornet
et al., 2012). For example, Cornet and colleagues
demonstrated the ability of HPV38 and HPV49 E6 to
inactivate p53, although the mechanisms for each HPV type
may not be the same. These functional differences may
translate to their differential involvement in BCC versus SCC
tumorigenesis by targeting signaling proteins implicated in
NMSC, such as TP53, PTCH1, and telomerase (Madan et al.,
2010). The functional activity of oncoproteins encoded for by
HPV types in genera a and g have not yet been characterized.
The clinic-based study design may introduce selection bias
if referral patterns differ between cases and controls. However,
in the current study, the cases and a portion of the controls
were selected from University of South Florida (USF) clinics
that serve the same underlying community. BCC cases were
significantly older than controls and tended to be male, but all
analyses adjusted for these factors. In addition, the age-
adjusted analysis restricted to a narrower age range revealed
findings similar to those obtained from the overall study
population, indicating that the observed associations are not
due to confounding by age. Men were significantly more likely
than women to be seropositive for genus-g HPV types.
However, the only statistically significant interaction observed
was between sex and genus-mu seropositivity in relationship
with BCC. Similar to the current study, a single study from the
United States (Karagas et al., 2010) reported a nonstatistically
significant higher seroprevalence for any HPV type in genus-b
among men compared with women. However, the study did
not discuss potential interaction effects between sex and
genus-b seropositivity in relation to BCC (Karagas et al., 2010).
Several strengths of the current case–control study should
also be noted. This is the first study to examine associations
between BCC and seroreactivity for cutaneous HPV types
outside of genus-a and -b utilizing the same multiplex
Table 4. Association between type-specific HPV
seropositivity and BCC
Controls (n¼300) BCC (n¼224)
HPV genus n (%) n (%) OR (95% CI)1
Any HPV type 256 (85.3) 203 (90.6) 1.72 (0.96–3.05)
a
2 29 (9.7) 29 (12.9) 1.55 (0.87–2.77)
3 36 (12) 43 (19.2) 1.70 (1.03–2.82)
7 22 (7.3) 14 (6.3) 0.87 (0.42–1.82)
10 17 (5.7) 22 (9.8) 1.70 (0.84–3.44)
27 33 (11) 42 (18.8) 2.18 (1.28–3.71)
57 22 (7.3) 21 (9.4) 1.39 (0.71–2.72)
77 47 (15.7) 40 (17.9) 1.18 (0.72–1.92)
b
Any b1 100 (33.3) 94 (42) 1.30 (0.89–1.90)
5 38 (12.7) 30 (13.4) 1.01 (0.59–1.75)
8 69 (23) 69 (30.8) 1.32 (0.87–2.00)
20 63 (21) 54 (24.1) 1.11 (0.72–1.73)
24 37 (12.3) 42 (18.8) 1.37 (0.82–2.28)
36 52 (17.3) 40 (17.9) 0.90 (0.55–1.46)
Any b2 143 (47.7) 114 (50.9) 1.14 (0.79–1.64)
9 75 (25) 57 (25.4) 0.88 (0.58–1.35)
15 76 (25.3) 67 (29.9) 1.18 (0.78–1.77)
17 77 (25.7) 59 (26.3) 1.06 (0.70–1.61)
23 61 (20.3) 52 (23.2) 1.28 (0.82–1.99)
38 74 (24.7) 58 (25.9) 1.05 (0.69–1.59)
107 48 (16) 33 (14.7) 0.83 (0.50–1.38)
Any b3 101 (33.7) 76 (33.9) 0.96 (0.65–1.42)
49 89 (29.7) 67 (29.9) 0.96 (0.65–1.44)
75 46 (15.3) 35 (15.6) 1.01 (0.61–1.68)
76 54 (18) 45 (20.1) 1.07 (0.67–1.70)
b4
(92) 50 (16.7) 30 (13.4) 0.78 (0.46–1.31)
b5
(96)5 45 (15) 33 (14.7) 0.86 (0.52–1.44)
g
4 103 (34.3) 84 (37.5) 1.11 (0.76–1.62)
48 64 (21.3) 56 (25) 1.23 (0.80–1.91)
50 47 (15.7) 34 (15.2) 1.01 (0.61–1.67)
65 78 (26) 62 (27.7) 0.98 (0.65–1.48)
88 20 (6.7) 13 (5.8) 1.05 (0.49–2.24)
95 67 (22.3) 55 (24.6) 1.00 (0.65–1.54)
101 33 (11) 24 (10.7) 0.97 (0.54–1.74)
103 13 (4.3) 15 (6.7) 1.37 (0.61–3.05)
Mu (1) 96 (32) 86 (38.4) 1.56 (1.06–2.30)
Nu (41) 34 (11.3) 26 (11.6) 1.00 (0.56–1.77)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HPV,
human papillomavirus; OR, odds ratio.
1ORs and 95% CIs adjusted for age and sex.
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serologic methods used in recent previously published studies
(Casabonne et al., 2007; Karagas et al., 2010), allowing for
direct comparisons across studies with regard to genus-a
and -b seroreactivity. A major strength of our study was the
unique opportunity to investigate the specificity of serologic
response and the presence of DNA for the same HPV type in
the BCC tumor tissues. Only one study in the published
literature has presented similar results among a Swedish/
Austrian population; however, the concordance between
seropositivity and DNA status was presented for NMSC
overall and not by skin cancer type (Andersson et al., 2008).
Furthermore, the type-specific multiplex genotyping assay
used for genera b and g HPV DNA detection afforded many
strengths including high sensitivity, allowing for the detection
of low amounts of viral genomes and high specificity for the
identification of specific HPV types in both single and multiple
infections (Gheit et al., 2007). Another strength of the current
study includes the full-body skin screening exams undergone
by all control subjects to identify previously undetected cases
of skin cancer.
In conclusion, the current study provided evidence suggest-
ing a potential association between cutaneous HPV infection
and BCC. However, cutaneous HPVs are ubiquitous in
healthy, immunocompetent populations, and the mechanisms
by which HPV may have a role in NMSC carcinogenesis are
not yet well understood. To rule out the possibility of reverse
causality, additional studies are necessary to address the
functional role of, and the natural history of, cutaneous HPV
infections as they relate to NMSC development.
MATERIALS AND METHODS
Study design and population
To investigate the association between cutaneous HPV infection and
BCC, a clinic-based case–control study was conducted in Tampa, FL.
The study design and population have been previously described in
detail (Rollison et al., 2012). Briefly, histologically confirmed BCC
cases were recruited from the USF Dermatology clinic (n¼ 236).
Control subjects were recruited from the affiliated USF Family
Table 5. Type-specific HPV DNA prevalence among
238 BCC tumor tissues
HPV DNAþ
HPV genus/type n (%)
Any b type 120 (50.4)
b Species
b1
5 31 (13.0)
8 31 (13.0)
12 9 (3.8)
14 7 (2.9)
19 3 (1.3)
20 2 (0.8)
21 0 (0.0)
24 35 (14.7)
25 3 (1.3)
36 21 (8.8)
47 10 (4.2)
93 9 (3.8)
b2
9 10 (4.2)
15 6 (2.5)
17 9 (3.8)
22 17 (7.1)
23 7 (2.9)
37 17 (7.1)
38 32 (13.5)
80 3 (1.3)
b3
49 0 (0.0)
75 4 (1.7)
76 18 (7.6)
b4
92 6 (2.5)
b5
96 7 (2.9)
Number of b HPV infections
1 Type 43 (18.1)
2 Types 31 (13.0)
3 Types 22 (9.2)
4 Types 9 (3.8)
X5 Types 15 (6.3)
Any a type1 7 (3.0)
2 0 (0.0)
3 0 (0.0)
10 4 (1.7)
27 2 (0.8)
57 1 (0.4)
Table 5. Continued
HPV DNAþ
HPV genus/type n (%)
Any g type 20 (8.4)
4 1 (0.4)
50 11 (4.6)
60 1 (0.4)
65 3 (1.3)
88 1 (0.4)
103 1 (0.4)
121 2 (0.8)
Mu1 (1) 1 (0.4)
Abbreviations: BCC, basal cell carcinoma; HPV, human papillomavirus.
1DNA prevalence estimation based on a sample size of 236 BCC tumor
tissues.
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Table 6. Association between genus-specific HPV seroposivity and BCC, stratified by HPV DNA status of the same
HPV type in the tumor
BCC DNA status
Positive Negative
HPV type Antibody status
Controls
n (%) n (%) OR (95% CI)1 n (%) OR (95% CI)1
Genus-b
N 300 97 98
Any b Negative 121 (40.3) 26 (26.8) 1.00 (Reference) 31 (37.8) 1.00 (Reference)
Positive 179 (59.7) 71 (73.2) 1.76 (1.03–3.01) 61 (62.2) 1.06 (0.65–1.72)
b1
5 Negative 262 (87.3) 21 (84) 1.00 (Reference) 86 (87.8) 1.00 (Reference)
Positive 38 (12.7) 4 (16) 1.17 (0.36–3.87) 12 (12.2) 0.91 (0.45–1.86)
8 Negative 231 (77) 14 (53.8) 1.00 (Reference) 73 (74.5) 1.00 (Reference)
Positive 69 (23) 12 (46.2) 2.77 (1.11–6.94) 25 (25.5) 1.02 (0.59–1.77)
20 Negative 237 (79) 0 (0) 1.00 (Reference) 74 (75.5) 1.00 (Reference)
Positive 63 (21) 2 (100) NA (NA) 24 (24.5) 1.13 (0.65–1.96)
24 Negative 263 (87.7) 22 (73.3) 1.00 (Reference) 82 (83.7) 1.00 (Reference)
Positive 37 (12.3) 8 (26.7) 1.80 (0.69–4.70) 16 (16.3) 1.15 (0.59–2.22)
36 Negative 248 (82.7) 14 (70) 1.00 (Reference) 81 (82.7) 1.00 (Reference)
Positive 52 (17.3) 6 (30) 1.12 (0.37–3.39) 17 (17.3) 0.85 (0.46–1.59)
b2
9 Negative 225 (75) 6 (66.7) 1.00 (Reference) 74 (75.5) 1.00 (Reference)
Positive 75 (25) 3 (33.3) 1.02 (0.22–4.63) 24 (24.5) 0.93 (0.54–1.60)
15 Negative 224 (74.7) 3 (60) 1.00 (Reference) 72 (73.5) 1.00 (Reference)
Positive 76 (25.3) 2 (40) 1.48 (0.23–9.48) 26 (26.5) 1.00 (0.59–1.71)
17 Negative 223 (74.3) 4 (57.1) 1.00 (Reference) 78 (79.6) 1.00 (Reference)
Positive 77 (25.7) 3 (42.9) 2.40 (0.49–11.70) 20 (20.4) 0.81 (0.46–1.43)
23 Negative 239 (79.7) 1 (20) 1.00 (Reference) 81 (82.7) 1.00 (Reference)
Positive 61 (20.3) 4 (80) 15.80 (1.60–155.00) 17 (17.3) 0.85 (0.46–1.56)
38 Negative 226 (75.3) 21 (75) 1.00 (Reference) 78 (79.6) 1.00 (Reference)
Positive 74 (24.7) 7 (25) 0.97 (0.37–2.56) 20 (20.4) 0.80 (0.45–1.43)
b3
75 Negative 254 (84.7) 3 (75) 1.00 (Reference) 87 (88.8) 1.00 (Reference)
Positive 46 (15.3) 1 (25) 2.14 (0.19–24.40) 11 (11.2) 0.67 (0.32–1.37)
b4
92 Negative 250 (83.3) 5 (100) 1.00 (Reference) 86 (87.8) 1.00 (Reference)
Positive 50 (16.7) 0 (0) 0.00 (NA) 12 (12.2) 0.64 (0.32–1.28)
b5
96 Negative 255 (85) 6 (85.7) 1.00 (Reference) 82 (83.7) 1.00 (Reference)
Positive 45 (15) 1 (14.3) 0.70 (0.08–6.42) 16 (16.3) 0.96 (0.50–1.82)
Genus-a2
N 300 7 186
Negative 194 (64.7) 3 (42.9) 1.00 (Reference) 98 (52.7) 1.00 (Reference)
Positive 106 (35.3) 4 (57.1) 2.53 (0.55–11.72) 88 (47.3) 1.64 (1.11–2.44)
Genus-g
N 300 17 178
Negative 145 (48.3) 6 (35.3) 1.00 (Reference) 55 (30.9) 1.00 (Reference)
Positive 155 (51.7) 11 (64.7) 1.40 (0.49–4.00) 123 (69.1) 1.97 (1.31–2.97)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HPV, human papillomavirus; NA, not applicable; OR, odds ratio.
1ORs and 95% CIs adjusted for age and sex.
2OR and 95% CI estimations based on a sample size of 193 BCC cases and 300 controls.
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and could not have a history of any type of cancer, including skin
cancer (n¼ 281). To exclude prevalent cases of undetected skin
cancer, all potential control participants underwent a full-body skin
cancer screening at the time of study enrollment. If a patient had a
suspicious lesion detected during the skin screening that was later
determined to be benign on the basis of pathology review, the patient
was included as a control (n¼ 77). If a patient’s screen-detected lesion
was histological-confirmed BCC, then that patient was included as a
case (n¼ 8). All eligible study participants were aged 18–80 years.
Participants completed a self-administered questionnaire, including
information on demographic (e.g., age, sex, race, education, and US
residency), lifestyle (e.g., history of smoking and alcohol consump-
tion), and skin cancer (e.g., eye, hair, and untanned skin color,
occupational sunlight exposure, history of blistering sunburn, cuta-
neous sensitivity, and tanning ability to sunlight exposure) risk factors.
Analyses were restricted to those individuals who reported being
White, with the exception of two non-White BCC cases and two non-
White controls retained to match to the non-White cases. Blood
samples were obtained from 226 (92.2%) BCC cases and 340 (95.0%)
controls. The final sample size for the analysis of cutaneous HPV
seroreactivity was 224 BCC cases and 300 controls. For BCC patients
undergoing surgical excision, a 3-mm punch of the residual BCC
tumor was obtained and flash-frozen in liquid nitrogen (n¼ 242).
Analyses were restricted to tumor specimens that tested positive for
b-globin (98.3%), corresponding to 238 BCC tumors from 230
individual patients. Information on both HPV seroreactivity and
DNA status of the tumor was available for 195 BCC cases. All study
procedures adhere to the Declaration of Helsinki Principles. All study
participants provided written informed consent, and the institutional
review board at USF approved all study procedures.
HPV antibody measurement
Sera were tested for antibodies to the major capsid protein L1 of
cutaneous HPV type(s) within genera a (2, 3, 7, 10, 27, 57, and 77), b
(5, 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, 96, and 107), g (4,
48, 50, 65, 88, 95, 101, and 103), mu (1), and nu (41). Sera were also
tested for antibodies to the VP1 capsid protein of two human
polyomaviruses, JC virus and KI virus, to test the specificity of
associations observed between cutaneous HPV and BCC. The anti-
body detection method used was based on glutathione-S-transferase
capture ELISA (Sehr et al., 2001, 2002) in combination with
fluorescent bead technology (Luminex) (Waterboer et al., 2005,
2006), as described previously. Individual cutoff values to define
HPV type–specific seropositivity were applied as described previously
to allow for the direct comparison of cutaneous HPV seroprevalence
across studies that used the same assay (Casabonne et al., 2007;
Michael et al., 2008).
DNA extraction
DNA extraction from fresh-frozen BCC tumor tissues was conducted
with the QIAGEN BioRobot EZ1 with the EZ1 DNA Tissue Kit
according to the manufacturer’s instructions (QIAGEN, Hilden,
Germany). Briefly, frozen tissues were incubated in proteinase K
and a buffer G2 (QIAGEN) at 56 1C until the tissue was completely
lysed. To monitor the possible occurrence of cross-contamination
between the different specimens during DNA extraction, tubes
containing only buffer were also included.
HPV DNA typing
HPV typing was performed by a type-specific multiplex
genotyping assay (Schmitt et al., 2006; Gheit et al., 2007; Ruer
et al., 2009; Schmitt et al., 2010). For specificity evaluation, cloned
HPV genomes and human specimens were used. PCR products were
obtained even when only 10 copies of the viral genome for each HPV
type were used as a template, demonstrating high sensitivity for type-
specific detection. The assay detects HPV DNA of 25 genus-b types
(5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49,
75, 76, 80, 92, 93, and 96), 16 genus-g types (4, 65, 95, 60, 48, 50,
88, 101, 103, 108, 109, 112, 116, 119, 121, and 123), 5 genus-a
types (2, 3, 10, 27, and 57), and the single type in genus-mu (1).
Two primers for the amplification of b-globin were added to
provide a positive control for the quality of the template DNA
(Saiki et al., 1988).
Statistical analysis
Logistic regression (LR) was used to estimate crude ORs and 95% CIs
between BCC and demographic, lifestyle, and phenotypic character-
istics. Seroprevalence for individual HPV types was estimated as the
proportion of patients who tested positive for antibodies to a single
HPV type. Subsequently, genus-specific HPV seroprevalence was
estimated as the proportion of patients who tested positive for
antibodies to at least one HPV type in a given genus. Using LR, OR
and 95% CI were estimated for the associations between BCC and
genus-specific and type-specific cutaneous HPV seropositivity. LR
was also used to assess the association between BCC and the number
of HPV types in a given genus for which an individual tested
seropositive. To test for trends in risk for BCC associated with
seropositivity to an increasing number of cutaneous HPV types within
a given genus, an ordinal variable was included in the model.
Bonferroni correction of P-values was used to account for multiple
comparisons, reducing the statistical significance level for genus-
specific HPV seropositivity to Po0.01 and type-specific HPV ser-
opositivity to Po0.002 (Iannacone et al., 2012).
BCC cases that provided tumor tissues were classified as either
positive or negative for the presence of HPV DNA for type(s) in
genera a, b, and g. The eight BCC cases that provided two tumor
tissues were categorized as genus-specific HPV DNA positive if at
least one of the two specimens tested positive for any HPV type
belonging to genera a, b, or g. To calculate OR and 95% CI for the
association between seropositivity to any genus-a, b, or g HPV type
and BCC, LR was used, stratifying by the presence and absence of
DNA in the tumor tissue. The analysis was restricted to HPV types
included in both antibody and PCR assays for genus-a (2, 3, 10, 27,
57), genus-b (5, 8, 20, 24, 36, 9, 15, 17, 23, 38, 75, 76, 92, 96), and
genus-g (4, 48, 50, 65, 88, 95, 101, 103).
Genus-b type-specific concordance was calculated among the BCC
cases as the proportion that tested seropositive for a given HPV type
and had DNA in their tumor tissue corresponding to the same HPV
type. Using LR, additional stratified analyses were then conducted to
compare genus-b type-specific HPV seropositivity between controls
and BCC cases that had DNA in their tumors corresponding to the
same HPV type for which antibodies were detected. LR was also used
to assess the associations between genus-b type-specific seropositivity
and BCC among cases with HPV DNA–negative tumor tissues.
Similar analyses were conducted for genus-a and genus-g HPV types
and BCC.
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Skin cancer risk factors were investigated as potential confounders
of the associations between genus-specific HPV seroreactivity and
BCC. With the exception of age and sex, none of the factors
investigated altered the ORs and corresponding 95% CIs for serolo-
gical associations by more than 10%. To examine residual confound-
ing resulting from the case–control differences in age and sex,
analyses were conducted stratified by sex and restricted to a
narrower age range of 40–69 years. The SAS statistical software
package (version 9.2; SAS Institute, Cary, NC) was used to conduct all
study analyses.
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